You are here

Our science / Clinical Trials / Find a Trial / NCT01604122

Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

Back to Search Print Save as PDF Bookmark Trial

NCT01604122

Last updated on December 5, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP), Transthyretin Cardiomyopathy (TTR-CM), Familial Amyloid Cardiomyopathy, Senile Systemic Amyloidosis (SSA)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adults (ages 18-85 years inclusive) diagnosed with TTR-FAP or TTR-CM and experiencing
symptoms or currently providing care for a patient with TTR-FAP or TTR-FAP

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Caregivers who formally care for a TTR-FAP or TTR-CM patient as part of their job
description and receive payment for their services.

NCT01604122
Pfizer
Completed
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Transthyretin (TTR) Amyloid Cardiomyopathy
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
NCT02791230
All Genders
18+
Years
Multiple Sites
Systemic Lupus Erythematosus
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
NCT00714116
All Genders
18+
Years
Multiple Sites
Familial Hypercholesterolemia
Atorvastatin Three Year Pediatric Study
NCT00827606
All Genders
6+
Years
Multiple Sites
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
Cross-sectional, Non-interventional Burden Of Disease (Bod) Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (Ttr-fap) Or Transthyretin Cardiomyopathy (ttr-cm) And Caregivers
This study is an online (web-based) or paper-based survey for patients with transthyretin familial amyloidosis polyneuropathy (TTR-FAP) and caregivers. The results will be used to describe the emotional, physical, and financial impact of having TTR-FAP or caring for someone who has the disease.
Convenience sample of patients and caregivers recruited through patient advocacy groups. Convenience sample.
Observational
Observational Model: Other
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Adults (ages 18-85 years inclusive) diagnosed with TTR-FAP or TTR-CM and experiencing symptoms or currently providing care for a patient with TTR-FAP or TTR-CM
  • Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP)
  • Transthyretin Cardiomyopathy (TTR-CM)
  • Familial Amyloid Cardiomyopathy
  • Senile Systemic Amyloidosis (SSA)
Other: No drug
No drug.
  • Patients
    Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
    Intervention: Other: No drug
  • Caregivers
    Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
    Intervention: Other: No drug
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1
July 18, 2016
July 27, 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults (ages 18-85 years inclusive) diagnosed with TTR-FAP or TTR-CM and experiencing symptoms or currently providing care for a patient with TTR-FAP or TTR-FAP

Exclusion Criteria:

  • Caregivers who formally care for a TTR-FAP or TTR-CM patient as part of their job description and receive payment for their services.
Not Provided
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01604122
B3461036
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now